Development
NeuroOne Medical Technologies Corporation
NMTC
$0.5817
-$0.0073-1.24%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -93.03% | -128.12% | -25.69% | -15.20% | 38.28% |
| Total Depreciation and Amortization | 63.51% | 87.13% | 80.95% | 54.04% | 42.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.22% | -11.90% | 13.02% | -5.74% | 33.54% |
| Change in Net Operating Assets | 59.05% | -108.17% | 179.54% | 29.75% | -1,566.61% |
| Cash from Operations | -9.08% | -385.20% | -11.52% | -10.24% | -30.35% |
| Capital Expenditure | -222.61% | 12.99% | -157.01% | -88.32% | 81.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Investing | -345.70% | 98.35% | 1,688.01% | 2,055.31% | 124.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -140.13% | -- | -- | -55,766.67% | 98.82% |
| Cash from Financing | 7,775.16% | -- | -- | 220,766.67% | -100.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.38% | 210.96% | 80.72% | 67.87% | -137.63% |